The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...

A study published earlier this year in the Journal of Neuro-Oncology indicates that sonodynamic therapy (SDT) safely destroys GBM cells while preserving healthy brain tissue. Using a noninvasive ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

December 31, 2025 – PRESSADVANTAGE – As pharmaceutical development becomes increasingly global and highly regulated, pharmacovigilance translation has moved from a supporting function to a central ...

President William Ruto has announced that his government will establish an Anti-Narcotics Unit within the Directorate of Criminal Investigations (DCI) to tackle alcohol and drug abuse. In his New Year ...

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

A San Diego startup may have created what the scientific community has talked about for decades – a kind of universal flu ...

A drug once designed for dengue virus, then quietly abandoned by industry, is suddenly back in the spotlight, and it may be ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), ...

Dana-Farber CEO outlines 2026 priorities: AI research, rare disease drug development, and plans for a new 300-bed hospital.